Pyxis Oncology Inc PYXS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)
-
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
-
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
-
Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
Trading Information
- Previous Close Price
- $3.44
- Day Range
- $3.38–3.52
- 52-Week Range
- $1.35–6.85
- Bid/Ask
- $3.50 / $3.65
- Market Cap
- $208.57 Mil
- Volume/Avg
- 276,995 / 493,618
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.53
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 55
- Website
- https://www.pyxisoncology.com
Comparables
Valuation
|
Metric
|
PYXS
|
ARTV
|
RVMD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.19 | — | 4.70 |
Price/Sales | 10.53 | 4.36 | 8,996.28 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PYXS
|
ARTV
|
RVMD
|
|---|---|---|---|
Quick Ratio | 9.22 | 4.43 | 15.10 |
Current Ratio | 9.53 | 4.59 | 15.42 |
Interest Coverage | — | — | — |
Quick Ratio
PYXS
ARTV
RVMD
Profitability
|
Metric
|
PYXS
|
ARTV
|
RVMD
|
|---|---|---|---|
Return on Assets (Normalized) | −22.62% | −16.21% | −28.36% |
Return on Equity (Normalized) | −28.59% | — | −32.03% |
Return on Invested Capital (Normalized) | −29.06% | — | −35.40% |
Return on Assets
PYXS
ARTV
RVMD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Tvkblbxfw | Hjgr | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Yksxllwj | Cptvbk | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dtqrxzfr | Hgwhsw | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Pbsmkwm | Cjhxyc | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Chrwyvlth | Qccv | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Jqchpfq | Lnk | $28.3 Bil | |||
| Moderna Inc
MRNA
| Ndrgpgh | Bnc | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Vdqvnmtsr | Hwqvy | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gxkjwdflj | Gzyttj | $13.3 Bil | |||
| Incyte Corp
INCY
| Yhtglsx | Wnwjzls | $13.0 Bil |
United States